NCT07485283: Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
- State
- Under way
- Phase
- Phase 4
- People
- 168,460 taking part
- Started
- 28 Apr 2026
- Primary completion
- Jun 2029
- Arms
- Recombinant Herpes Zoster Vaccine (Shingrix).
- Results
- None posted
- 20 Mar 2026: Trial registered
- 28 Apr 2026: Trial started